Background: The scarcity of knowledge regarding the epidemiology and temporal patterns of viral skin diseases worldwide poses significant challenges to their control and management.
Methods: We analyzed the global incidence, prevalence, and age-standardized rates (ASR) of disability-adjusted life years (DALYs) for viral skin diseases in 2021. To examine temporal trends from 1990 to 2021, we employed the EPAC model, assessing changes by country, gender, age, Socio-demographic Index (SDI), and GBD regions. Additionally, we utilized the age-period-cohort (APC) model and the Bayesian age-period-cohort (BAPC) model to forecast the burden of viral skin diseases for the next 25 years.
Results: In 2021, the global burden of viral skin diseases was estimated at 84.7 million incident cases, with a prevalence of over 130 million cases and 4.2 million DALYs. Males experienced a slightly higher ASR burden than females. The highest burden was observed among individuals aged 10 to 19, with significant geographical variations in cases and ASR, particularly in high SDI regions. Unexpected rises in incidence were noted in East Asia and Sub-Saharan Africa in the detected period. Despite modest declines in ASPR and ASDR, the global ASIR displayed a significant upward trend.
Conclusion: Our study provides detailed data on the global impact of viral skin diseases from 1990 to 2021, highlighting the need for continuous surveillance and tailored interventions to manage and reduce the effects of these diseases. Targeted public health measures are essential to address and mitigate the global health burden of viral skin diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11879981 | PMC |
| http://dx.doi.org/10.3389/fpubh.2025.1464372 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced localized pressure-mediated non-viral gene delivery.
Drug Deliv Transl Res
March 2025
Regenerative Medicine & Cellular Therapies Division, School of Pharmacy, The University of Nottingham Biodiscovery Institute (BDI), University of Nottingham, Nottingham, NG7 2RD, UK.
Topically applied therapies must not only be effective at the molecular level but also efficiently access the target site which can be on milli/centimetre-scales. This bottleneck is particularly inhibitory for peptide and nucleic acid macromolecule drug delivery strategies, especially when aiming to target wounded, infected, and poorly perfused tissues of significant volume and geometry. Methods to drive fluid-flow or to enhance physical distribution of such formulations after local administration in accessible tissues (skin, eye, intestine) would be transformative in realizing the potential of such therapeutics.
View Article and Find Full Text PDFCase report: The first case of Mpox in a patient with HIV in Burundi.
Front Med (Lausanne)
February 2025
Department of Dermatology, College of Health Sciences and Medicine, Bahir Dar University, Bahir Dar, Ethiopia.
Introduction: Mpox is a viral disease that primarily affects individuals living in endemic regions. The 2022 outbreak notably impacted HIV-positive individuals, who were disproportionately affected. This report describes the first confirmed case of Mpox in Burundi, involving an HIV-positive patient with advanced disease.
View Article and Find Full Text PDFInteractions Between Commensal Microbes and Mosquito-Borne Viruses.
Annu Rev Virol
March 2025
1New Cornerstone Science Laboratory, Tsinghua University-Peking University Joint Center for Life Sciences, School of Basic Medical Sciences, Tsinghua University, Beijing, China; email:
Emerging and re-emerging mosquito-borne viruses pose a significant threat to global public health. Unfortunately, effective preventive and therapeutic measures are scarce. An in-depth understanding of the mechanisms regulating viral pathogenesis, vector competence, and viral transmission between mammalian hosts and vectors may lay the foundations for new preventive and therapeutic approaches.
View Article and Find Full Text PDFActivin A activation of Smad3 mitigates innate inflammation in mouse models of psoriasis and sepsis.
J Clin Invest
March 2025
Mucosal Immunology Section, National Institutes of Dental and Craniofacial Research, NIH, Bethesda, United States of America.
Phosphorylation of Smad3 is a critical mediator of TGF-β signaling, which plays an important role in regulating innate immune responses. However, whether Smad3 activation can be regulated in innate immune cells in TGF-β-independent contexts remains poorly understood. Here, we show that Smad3 is activated through the phosphorylation of its C-terminal residues (pSmad3C) in murine and human macrophages in response to bacterial and viral ligands, which is mediated by Activin A in a TGF-β independent manner.
View Article and Find Full Text PDFRituximab for people with multiple sclerosis.
Cochrane Database Syst Rev
March 2025
Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Background: Multiple sclerosis (MS) is the most common neurological cause of disability in young adults. Off-label rituximab for MS is used in most countries surveyed by the International Federation of MS, including high-income countries where on-label disease-modifying treatments (DMTs) are available. This updates the 2021 version of the review.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!